Utilising execution systems to improve cell and gene therapy data integrity and product consistency
Posted on July 15, 2020 by Helena Graham
Full Article Source: Manufacturing Chemist
Cell and Gene therapy has become a vital element of modern medicine and presents opportunities for much improved treatment of cancer and other diseases. By equipping a patient’s cells with a means to identify and ameliorate other damaged/damaging tissues and cells within their bodies, it brings new hope to those with illnesses traditionally thought to be incurable.
Following significant scientific advancements in personalised therapies, investment and research in the sector has risen steeply in recent years. The global cell therapy market is expected to reach $8.21 billion by 2025 (Source: Frost and Sullivan), making it the fastest growing sector in the regenerative medicine industry. Despite these advancements, labour-intensive, manual processes and small batch sizes are creating obstacles and driving high costs for these therapies on an industrial scale.
Director of Biological Operations Technology, Cory Brown recently discussed the topic in a Manufacturing Chemist article, exploring the production challenges of cell and gene therapies and how the adoption of manufacturing execution systems (MES) can help. You can access the full article here
At Zenith Technologies, a Cognizant Company, we offer a range of MES solutions for the biotechnology sector and have cultivated extensive and varied skill sets over the past 20 years.
Find out more about our manufacturing technology solutions for the biotechnology sector here.